Inhaled pre-prandial human insulin versus subcutaneous injected insulin aspart in subjects with diabetes and chronic obstructive pulmonary disease: a 52-week open label, multicentre, randomized, parallel trial to investigate long-term safety.

Trial Profile

Inhaled pre-prandial human insulin versus subcutaneous injected insulin aspart in subjects with diabetes and chronic obstructive pulmonary disease: a 52-week open label, multicentre, randomized, parallel trial to investigate long-term safety.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 04 Mar 2017

At a glance

  • Drugs Insulin (Primary) ; Insulin aspart
  • Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
  • Focus Adverse reactions
  • Acronyms iINHALE-8
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 14 Jan 2009 Planned end date changed from 1 Dec 2009 to 1 Mar 2008 as reported by ClinicalTrials.gov.
    • 24 Jun 2008 Actual end date changed from Jan 2008 to Mar 2008 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top